CN115322451A - 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 - Google Patents
一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN115322451A CN115322451A CN202211055899.8A CN202211055899A CN115322451A CN 115322451 A CN115322451 A CN 115322451A CN 202211055899 A CN202211055899 A CN 202211055899A CN 115322451 A CN115322451 A CN 115322451A
- Authority
- CN
- China
- Prior art keywords
- nano
- composite hydrogel
- hydroxyapatite
- solution
- hydroxyapatite composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 181
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 147
- 239000002131 composite material Substances 0.000 title claims abstract description 142
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 60
- 229920001661 Chitosan Polymers 0.000 claims abstract description 29
- 229920002307 Dextran Polymers 0.000 claims abstract description 26
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 26
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 13
- 201000001245 periodontitis Diseases 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 15
- 239000002105 nanoparticle Substances 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 14
- 239000012736 aqueous medium Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 208000007117 Oral Ulcer Diseases 0.000 claims description 5
- 229920001503 Glucan Polymers 0.000 claims description 4
- 239000012154 double-distilled water Substances 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 17
- 239000002262 Schiff base Substances 0.000 abstract description 5
- 150000004753 Schiff bases Chemical class 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000003239 periodontal effect Effects 0.000 abstract description 4
- 239000012620 biological material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 48
- 210000003743 erythrocyte Anatomy 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- 238000001514 detection method Methods 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 9
- 230000023597 hemostasis Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 206010018910 Haemolysis Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000008588 hemolysis Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000011056 performance test Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000002399 aphthous stomatitis Diseases 0.000 description 4
- 239000001046 green dye Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000001044 red dye Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000013168 hemostasis test Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/02—Dextran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Abstract
本发明公开了一种纳米羟基磷灰石复合水凝胶及其制备方法和应用,属于先进生物材料领域。本发明设计了一种动态席夫碱反应,将羧甲基壳聚糖、氧化葡聚糖和纳米羟基磷灰石相结合,制备了兼顾三者优势的多功能水凝胶。该复合水凝胶具有优异的生物相容性、可注射性、自我修复性、粘性和抗菌性能,可以调节细胞微环境,局部止血,进而修复受损的牙周组织,在治疗牙周炎方面、制备止血材料方面显示出巨大潜力。
Description
技术领域
本发明属于先进生物材料领域,具体涉及一种纳米羟基磷灰石复合水凝胶及其制备方法和应用。
背景技术
羟基磷灰石具有良好的生物相容性和骨传导性,是人类和动物骨骼和牙齿的主要无机成分。它可以在短时间内与人体软组织和硬组织紧密结合,并释放无害离子,能够参与人体的新陈代谢,刺激或诱发骨质增生,促进缺损组织的修复,已被广泛用于人体骨组织的修复。然而,作为一种烧结材料,羟基磷灰石的脆性和抗疲劳性差,严重阻碍了其临床应用。选择合适的有机基质材料与羟基磷灰石紧密结合,制备具有良好生物活性、机械性能和降解性能的复合仿生材料逐渐成为当前研究的重点。
然而,传统的仿生骨修复材料制备过程中,因有机基质材料的性能存在缺陷,选择合适的有机基质材料是非常困难的。如高密度聚乙烯不具备生物降解性;胶原纤维力学性能差,降解速度快,机械强度低;淀粉基复合材料的复合过程比较困难;聚乳酸(PLA)在人体内迅速降解,导致机械性能迅速丧失。同时,许多有机基质材料可能在植入部位出现无菌性炎症反应和溶骨性变化。因此,发现一种合适的有机基质材料与羟基磷灰石结合很有必要。
水凝胶类材料含水量高,具有良好的生物相容性和适当的物理特性,能够为细胞粘附、增殖和分化提供最佳的生物环境。天然多糖类水凝胶,具有良好的生物相容性、生物降解性、生物安全性、抗菌活性、抗炎活性等特性,被广泛用作骨组织再生支架的基质材料。然而这类水凝胶往往在成骨、血管生成和机械性能表现出明显不足,严重限制了它们在临床上的实际应用。
发明内容
为了解决现有技术的不足,本发明的目的是提供一种纳米羟基磷灰石复合水凝胶及其制备方法和应用。本发明设计一种动态席夫碱反应,将羧甲基壳聚糖、氧化葡聚糖和纳米羟基磷灰石相结合,制备了兼顾三者优势的多功能水凝胶。该复合水凝胶具有优异的生物相容性、可注射性、自我修复性、粘性和抗菌性能,可以调节细胞微环境,局部止血,进而修复受损的牙周组织,在治疗牙周炎等方面显示出巨大潜力。
为了实现上述目的,本发明的技术方案为:
一方面,一种纳米羟基磷灰石复合水凝胶,由多糖和纳米粒子在水性介质中交联而成;
所述纳米粒子包括纳米羟基磷灰石或包含纳米羟基磷灰石的粒子;
所述多糖包括葡聚糖、羧甲基壳聚糖、壳聚糖、透明质酸和羟乙基壳聚糖中的两种。
另一方面,上述的纳米羟基磷灰石复合水凝胶的制备方法,包括以下步骤:
将一种多糖溶解在水性介质中,得到溶液A;
将纳米粒子加到溶液A中,得到溶液B;
将另一种多糖溶于水性介质中,得到溶液C;
将溶液B与溶液C混合,得到纳米羟基磷灰石复合水凝胶。
第三方面,上述的纳米羟基磷灰石复合水凝胶是在制备抗炎药物、止血材料中的应用,优选的,所述药物包括用于治疗牙周炎、牙龈炎、口腔溃疡。
本发明的有益效果为:
本发明设计一种动态席夫碱反应,将羧甲基壳聚糖、氧化葡聚糖和纳米羟基磷灰石相结合,制备了兼顾三者优势的多功能水凝胶。该复合水凝胶具有优异的生物相容性、可注射性、自我修复性、粘性和抗菌性能,可以调节细胞微环境,局部止血,进而修复受损的牙周组织,在治疗牙周炎等方面显示出巨大潜力。
本发明通过在由氧化葡聚糖和羧甲基壳聚糖组成的水凝胶中加入一定量的纳米羟基磷灰石,合成了一种在粘附性、止血性和抗菌性能上表现更加优异的新型复合水凝胶。经过SEM检测,该水凝胶具有多孔结构,即使在不同方向的急速的水流冲击力的作用下,纳米羟基磷灰石复合水凝胶在猪皮上依然发生了强有力的粘附。通过纳米羟基磷灰石复合水凝胶的自组装试验,在37℃下,两半不同颜色的复合水凝胶可以牢牢的组合在一起。该复合水凝胶的血液相容性同样良好,不会对红细胞造成损害。对该复合水凝胶在小鼠肝脏上进行了止血试验,用注射器将复合水凝胶注射到伤口上,10秒后即可快速止血,表明了其优良的止血性能。该复合水凝胶对金黄色葡萄球菌和大肠杆菌的抗菌效果较好,特别是对大肠杆菌的抗菌效果达到90%以上。因此,纳米羟基磷灰石复合水凝胶在止血和抗菌方面具有良好的应用前景。
附图说明
构成本发明的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。
图1为本发明实施例1制备的纳米羟基磷灰石复合水凝胶过程图;
图2为本发明对比例1制备的未加入纳米羟基磷灰石的复合水凝胶的SEM图像及孔径分布图;
图3为本发明实施例1制备的纳米羟基磷灰石复合水凝胶的SEM图像及孔径分布图;
图4为通过溶胀试验测定实施例1与对比例1得到的水凝胶在PBS(pH=7)中的溶胀率数据图;
图5为纳米羟基磷灰石、未加入纳米羟基磷灰石的复合水凝胶和纳米羟基磷灰石复合水凝胶的红外吸收光谱;
图6为本发明实验例2纳米羟基磷灰石复合水凝胶的粘附性检测图,其中,A-C为染色的纳米羟基磷灰石复合水凝胶在不同扭曲角度的猪皮表面上的图片,D-F为染色的纳米羟基磷灰石复合水凝胶在不同角度的急速水流冲击下在猪皮表面附着的照片;
图7为本发明实验例3纳米羟基磷灰石复合水凝胶的自愈性能检测图,其中A为绿色染料染色的纳米羟基磷灰石复合水凝胶,B为红色染料染色的纳米羟基磷灰石复合水凝胶,(C)为红绿两半结合的纳米羟基磷灰石复合水凝胶发生自愈图;
图8为本发明实验例3纳米羟基磷灰石复合水凝胶的溶血性能测试中各组溶血情况图片;
图9为本发明实验例3纳米羟基磷灰石复合水凝胶的溶血性能测试中各组溶血率柱状图;
图10为本发明实验例4纳米羟基磷灰石复合水凝胶对红细胞的粘附性检测中复合水凝胶表面红细胞的SEM图,其中,A为放大2000倍下,不含纳米羟基磷灰石的复合水凝胶表面红细胞的粘附;B为放大2000倍下,纳米羟基磷灰石复合水凝胶表面红细胞的粘附;C为放大5000倍下,不含纳米羟基磷灰石的复合水凝胶表面红细胞的粘附;D为放大5000倍下,纳米羟基磷灰石复合水凝胶表面红细胞的粘附;
图11为本发明实验例5纳米羟基磷灰石复合水凝胶的止血性能检测中不同复合水凝胶以及空白对照组在小鼠肝脏止血的特定时间拍摄的图片;
图12为本发明实验例5纳米羟基磷灰石复合水凝胶的止血性能检测中不同复合水凝胶以及空白对照组小鼠肝脏的止血时间图;
图13为本发明实验例5纳米羟基磷灰石复合水凝胶的止血性能检测中不同复合水凝胶以及空白对照组小鼠肝脏的血液流失质量图;
图14为本发明实验例6纳米羟基磷灰石复合水凝胶体外抗菌试验中抗菌活性评估图,其中,A为与水凝胶共培养后琼脂平板上大肠杆菌活体细菌菌落图;B为与水凝胶共培养后琼脂平板上金黄色葡萄球菌活体细菌菌落图;
图15为本发明实验例6纳米羟基磷灰石复合水凝胶体外抗菌试验中各组复合水凝胶与金黄色葡萄球菌和大肠杆菌共培养后琼脂平板上菌落平均数。
具体实施方式
应该指出,以下详细说明都是示例性的,旨在对本发明提供进一步的说明。除非另有指明,本文使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同含义。
需要注意的是,这里所使用的术语仅是为了描述具体实施方式,而非意图限制根据本发明的示例性实施方式。如在这里所使用的,除非上下文另外明确指出,否则单数形式也意图包括复数形式,此外,还应当理解的是,当在本说明书中使用术语“包含”和/或“包括”时,其指明存在特征、步骤、操作、器件、组件和/或它们的组合。
鉴于现有羟基磷灰石的脆性和抗疲劳性差阻碍了其在临床中的应用,非常有必要发现一种合适的有机基质材料与其结合来提高其性能,扩展其应用;水凝胶在成骨、血管生成和机械性能上的不足同样严重限制了其在临床上的实际应用,本发明提出了一种纳米羟基磷灰石复合水凝胶及其制备方法和应用。
本发明的一种典型实施方式,提供了一种纳米羟基磷灰石复合水凝胶,由多糖和纳米粒子在水性介质中交联而成;
所述纳米粒子包括纳米羟基磷灰石或包含纳米羟基磷灰石的粒子;
所述多糖包括葡聚糖、羧甲基壳聚糖、壳聚糖、透明质酸和羟乙基壳聚糖中的两种。
该实施方式的一些实施例中,所述多糖为葡聚糖、羧甲基壳聚糖。
该实施方式的一些实施例中,所述葡聚糖的分子量为10-200kDa,优选为20-150kDa。
该实施方式的一些实施例中,所述纳米粒子的质量浓度为5-15wt%,优选为10wt%。
本发明的另一种典型实施方式,提供了上述的纳米羟基磷灰石复合水凝胶的制备方法,包括以下步骤:
将一种多糖溶解在水性介质中,得到溶液A;
将纳米粒子加到溶液A中,得到溶液B;
将另一种多糖溶于水性介质中,得到溶液C;
将溶液B与溶液C混合,得到纳米羟基磷灰石复合水凝胶。
该实施方式的一些实施例中,溶液A的具体制备方法为:将葡聚糖和高碘酸钠溶解在水中并搅拌合成氧化葡聚糖溶液。
优选的,葡聚糖和高碘酸钠的摩尔比为1-3:1,进一步优选为2:1。
该实施方式的一些实施例中,溶液B的具体制备方法为:将纳米粒子加入到10wt%的溶液A中并均匀搅拌。
优选的,纳米粒子与10wt%的溶液A的比例为1:5-20,进一步优选为1:5。
该实施方式的一些实施例中,溶液C的具体制备方法为:将羧甲基壳聚糖溶于双蒸水中,得到羧甲基壳聚糖水溶液,优选的,羧甲基壳聚糖水溶液的浓度为10wt%。
该实施方式的一些实施例中,溶液B与溶液C的体积比为1-2:1-2,优选为1:1。
本发明的第三种典型实施方式,提供了上述的纳米羟基磷灰石复合水凝胶是在制备抗炎药物、止血材料中的应用,优选的,所述药物包括用于治疗牙周炎、牙龈炎、口腔溃疡。
牙周炎的主要表现是病原微生物定植引起的局部炎症反应,伴随牙龈出血和牙槽骨吸收,这常常导致牙齿过早失去功能,甚至脱落。牙龈炎指发生于牙龈组织的急慢性炎症,表现为牙龈出血,红肿,胀痛,继续发展侵犯硬组织,形成牙周炎。口腔溃疡的发生是多种因素综合作用的结果,但口腔微生物如血链球菌等在口腔溃疡的发生、发展中可能起重要作用。本发明设计一种动态席夫碱反应,将羧甲基壳聚糖、氧化葡聚糖和纳米羟基磷灰石相结合,制备了兼顾三者优势的多功能水凝胶。该复合水凝胶具有优异的生物相容性、可注射性、自我修复性、粘性和抗菌性能,可以调节细胞微环境,局部止血,进而修复受损的牙周组织,在治疗牙周炎等方面显示出巨大潜力。
为了使得本领域技术人员能够更加清楚地了解本发明的技术方案,以下将结合具体的实施例详细说明本发明的技术方案。
以下实施例合成所需材料:羧甲基壳聚糖、葡聚糖和高碘酸钠(由中国上海原野生物技术有限公司提供)。纳米羟基磷灰石(由上海阿拉丁生物技术有限公司提供)。
实施例1
一种纳米羟基磷灰石复合水凝胶的制备方法,具体步骤如下:
(1)将葡聚糖(20-150kDa)和高碘酸钠以摩尔比2:1的比例溶解在水中并搅拌24h以合成氧化葡聚糖溶液。
(2)称取2克纳米羟基磷灰石加入到10毫升10wt%的氧化葡聚糖水溶液中并均匀搅拌。
(3)称取1克羧甲基壳聚糖并将其溶于10毫升双蒸水中,得到10wt%的羧甲基壳聚糖水溶液。
(4)将(2)、(3)中得到的两种溶液按体积比为1:1混合,得到含有10%的纳米羟基磷灰石复合水凝胶。
如图1所示,纳米羟基磷灰石复合水凝胶的合成过程,将含有纳米羟基磷灰石的氧化葡聚糖水溶液和羧甲基壳聚糖溶液以1:1的比例混合时,纳米羟基磷灰石复合水凝胶在席夫碱的作用下形成。
对比例1
一种复合水凝胶,具体步骤如下:
(1)将葡聚糖(20-150kDa)和高碘酸钠以摩尔比2:1的比例溶解在水中并搅拌24h以合成氧化葡聚糖溶液。
(2)称取1克羧甲基壳聚糖并将其溶于10毫升双蒸水中,得到10wt%的羧甲基壳聚糖水溶液。
(3)将(1)、(2)中得到的两种溶液按体积比为1:1混合,得到不含纳米羟基磷灰石的复合水凝胶。
以下实验例将实施例1与对比例1得到的纳米羟基磷灰石复合水凝胶及不含纳米羟基磷灰石的复合水凝胶作为不同样本,同时设置对照组进行检测。
实验例1
(1)纳米羟基磷灰石复合水凝胶的特性分析
使用傅里叶红外光谱(FTIR,Thermo Fisher Scientific,Waltham,Ma,USA)和扫描电子显微镜(SEM,TESCAN Co.,Ltd.,VEGA3,China)对实施例1、对比例1得到的复合水凝胶材料进行特征观察。
(2)纳米羟基磷灰石水凝胶溶胀行为的检测
取不同质量纳米羟基磷灰石复合水凝胶以及对比例1的复合水凝胶,加入一定体积的磷酸缓冲盐溶液(PBS,PH=7)溶液,在37℃下浸泡,直至达到溶胀平衡。测量复合水凝胶的质量时,用镊子将水凝胶取出,在吸水纸上擦干,称出水凝胶的水分。(水凝胶的膨胀率是用重量法测定的)
分析及检测结果:
通过图2可以看到,对比例1得到的复合水凝胶具有多孔结构,并且孔隙均匀分布,在对孔隙大小进行量化后,平均孔径为216.99微米。如图3所示,加入纳米羟基磷灰石后,复合水凝胶中的孔径变得不均匀,是因为加入纳米羟基磷灰石后凝胶化速度较快,混合变得不均匀。加入纳米羟基磷灰石后,复合水凝胶的孔径减小,平均孔径为170.75μm。
如图4所示,从水凝胶溶胀实验来看,两种复合水凝胶都能在短时间内吸收足够的水,在1小时内达到饱和,1小时后水凝胶的溶胀率下降,水凝胶中的溶液在PBS溶液中处于动态吸水平衡。在PBS(pH=7)溶液中,两种水凝胶在120分钟后形状没有再变化,保持了稳定的结构。
傅里叶红外光谱被用来检测单独的纳米羟基磷灰石和纳米羟基磷灰石复合水凝胶的红外吸收光谱。如图5所示,单独的纳米羟基磷灰石在1020cm-1和564cm-1处有PO3 4-的吸收峰,而HPO2 4-的吸收峰在605cm-1。未加入纳米羟基磷灰石的复合水凝胶在1590cm-1出现氧化葡聚糖中C=O的振动峰。加入纳米羟基磷灰石后,复合水凝胶中的吸收峰在564cm-1、603cm-1和1030cm-1表现明显,所以纳米羟基磷灰石被成功加载到复合水凝胶中,同时凝胶中C=O的波峰明显增强,证明复合水凝胶仍然能够成功凝胶化。
实验例2
纳米羟基磷灰石复合水凝胶的粘附性检测
选择猪皮进行测试,用于模拟水凝胶材料在人体皮肤表面的粘附性。将实施例1的溶液B、C通过双混合针管注射到猪皮表面,在猪皮表面形成纳米羟基磷灰石复合水凝胶。通过对猪皮形状的改变来检测复合水凝胶在组织表面的粘附力。具体为:在溶液B中加入一定量的红色或绿色染料,用两根无菌医用针头分别取1ml溶液B和溶液C,加入混合针管,注射在猪皮表面。在凝胶化后,对不同组的猪皮拍摄照片。
检测结果:
如图6所示,通过双混合针头将水凝胶注射到猪皮肤表面,纳米羟基磷灰石复合水凝胶可以牢固地贴在不同扭曲角度的猪皮表面(图6A-C)。使用不同角度的急速水流对猪皮表面的水凝胶进行剧烈冲击,纳米羟基磷灰石复合水凝胶都能牢固地贴在猪皮上(图6D-F)。
说明纳米羟基磷灰石复合水凝胶在巨大的冲击力下仍能牢牢封闭伤口,避免了因水凝胶开裂而导致的再次受伤。
实验例3
纳米羟基磷灰石复合水凝胶的自愈性能检测和溶血性能测试
(1)纳米羟基磷灰石复合水凝胶的自我修复能力
在两份等量的溶液B中,分别加入红色和绿色的染料。将不同组溶液用双混合注射器注入圆形模具中。凝胶化5分钟后,用刀片将两种不同颜色的纳米羟基磷灰石复合水凝胶切成两半。将两个不同颜色的半圆形纳米羟基磷灰石复合水凝胶放在同一个圆形模具中,一段时间后,观察并记录纳米羟基磷灰石复合水凝胶的自我修复情况。
测试结果:
水凝胶的自愈特性可以保持结构的完整性,恢复止血性能。在纳米羟基磷灰石复合水凝胶中加入绿色和红色染料以制备两种不同颜色的水凝胶,如图7A和图7B所示。将不同颜色的复合水凝胶从中间切开,将一半绿色纳米羟基磷灰石复合水凝胶和一半红色纳米羟基磷灰石复合水凝胶分别放在一起。10分钟后,在重力作用下,不同颜色拼在一起的纳米羟基磷灰石复合水凝胶可以用镊子完整地提起,另一半水凝胶不会移位,确保了纳米羟基磷灰石复合水凝胶的自愈特性(图7C)。
(2)纳米羟基磷灰石复合水凝胶的生物相容性
纳米羟基磷灰石复合水凝胶在止血过程中会接触血液,通过检查复合水凝胶的溶血特性来评估材料的血液相容性。血液相容性测试的目的是观察材料是否会使红细胞破裂。
根据实施例1以及对比例1的步骤,分别制备200uL未加入纳米羟基磷灰石的复合水凝胶和纳米羟基磷灰石复合水凝胶,用PBS溶液(pH=7)洗涤三次后,放入到1mL PBS(pH=7)溶液中。根据相关法律和机构指南,对健康志愿者的全血进行收集。将1毫升全血加入到5毫升的PBS(pH=7)溶液中,混合均匀,从混合的血液中取50uL然后加入到含有水凝胶的PBS溶液(pH=7)中。将上述四组(即双蒸馏水处理组对照组、空白组、复合水凝胶组、纳米羟基磷灰石复合水凝胶组)混合溶液置于37℃培养箱中1小时。
测试结果:
如图8所示,在离心后,对照组的上层溶液中含有大量的鲜红色血液。而其他三组的红细胞都沉积在离心管的底部,上层溶液无色透明,与空白组相似。这表明未加入纳米羟基磷灰石水的复合水凝胶和纳米羟基磷灰石复合水凝胶对红细胞都没有溶血活性。从柱状图图9中可以得出,未加入纳米羟基磷灰石的复合水凝胶和纳米羟基磷灰石复合水凝胶的溶血率都低于5%,且纳米羟基磷灰石复合水凝胶组的溶血率低于复合水凝胶组的,这表明在凝胶中加入纳米羟基磷灰石后进一步提高了其血液相容性。
实验例4
纳米羟基磷灰石复合水凝胶对红细胞的粘附性检测
红细胞可以通过纳米羟基磷灰石复合水凝胶的席夫碱反应粘附聚集在其表面,并加速自身的凝固过程。为了验证这一点,本发明用全血验证了有无纳米羟基磷灰石的复合水凝胶对红细胞的凝固效果。
根据实施例1、与对比例1的制备方法,分别制备100μL未加入纳米羟基磷灰石的复合水凝胶和纳米羟基磷灰石复合水凝胶,置于12孔板中,取出200μL抗凝全血滴在水凝胶表面,去除水凝胶表面的非粘附红细胞,用2.5%戊二醛溶液用PBS溶液稀释后在4℃下固定24小时,干燥后,在SEM下观察不同组复复合水凝胶表面的粘附形态。
检测结果:
如图10所示,纳米羟基磷灰石复合水凝胶(Gel-nHA)可以被红细胞粘附上并保护其完整性。放大5000倍后,观察红细胞的形态,发现粘附在不含有纳米羟基磷灰石的复合水凝胶上的红细胞形态良好,没有出现细胞膜破裂的情况(图10C)。同样,在纳米羟基磷灰石复合水凝胶表面的红细胞的形态也没有出现破裂(图10D),且吸附红细胞数目更多。因此,纳米羟基磷灰石复合水凝胶可以将红细胞粘附在表面而不损伤红细胞,更有利于血凝块的形成,为止血创造良好的条件。
实验例5
纳米羟基磷灰石复合水凝胶的止血性能检测
纳米羟基磷灰石复合水凝胶表现出很强的粘附性和优良的外部止血性能。因此,对不同组水凝胶的止血活性进行了研究。具体为:建立了一个小鼠止血模型,对小鼠肝脏进行止血,设立了空白组(即没有对小鼠肝脏伤口做任何处理的组)和不含纳米羟基磷灰石的复合水凝胶作为对照组。给小鼠注射了200μl4%的水合氯醛,麻醉后取出肝脏,将肝脏放在事先称好重量的滤纸上,同时用手术刀在肝脏上划出一个长3mm、深1mm的伤口,用注射器将制备好的不同组水凝胶注入伤口进行止血,此时开始计时,在0、15、30、60、120、240s对小鼠肝脏的止血部位进行拍照,记录滤纸上血液的变化。5分钟后,取出滤纸,称出滤纸的质量,根据滤纸前后的质量之差,计算小鼠肝脏的失血量。
检测结果:
从图11可以看出,空白组在240s时小鼠血液基本凝固,而纳米羟基磷灰石复合水凝胶在注射15s内小鼠肝脏部位基本无出血发生。
通过对小鼠肝脏出血部位的观察,空白组小鼠肝脏血液的自凝时间为290s(图12),而经水凝胶处理的伤口,肝脏的出血时间缩短为10s(图12),显示出良好的止血效果。当将纳米羟基磷灰石复合水凝胶注入小鼠肝脏出血的伤口,止血时间在10s以内(图12)。因此,加入纳米羟基磷灰石后,复合水凝胶的止血效果不受影响。
对小鼠的失血量进行了称重和量化,对于空白组,小鼠的失血量达到160mg,而对于凝胶组和纳米羟基磷灰石复合凝胶组,小鼠肝脏的失血量平均值分别为23.3mg和20mg(图13)。因此,纳米羟基磷灰石复合水凝胶具有更明显的止血效果。
实验例6
纳米羟基磷灰石复合水凝胶体外抗菌试验
皮肤是保护人体的屏障,皮肤破损后细菌通过伤口进入体内,造成伤口被细菌感染。因此,水凝胶是在止血的同时需要避免细菌的入侵。本发明通过水凝胶在体外的抗菌实验,验证了纳米羟基磷灰石复合水凝胶的抗菌能力。
首先,根据实施例1以及对比例1的制备方法,分别制备200μL未加入纳米羟基磷灰石的复合水凝胶和纳米羟基磷灰石复合水凝胶,在超净工作台中紫外线照射30min后,将其置于相同浓度的细菌肉汤中,在37℃的细菌培养箱中共培养了12h,之后将共培养的细菌肉汤用PBS(pH=7)稀释10-6倍,取样20μL稀释后的PBS细菌肉汤均匀地铺在琼脂平板上,然后将平板放置在37℃细菌培养箱中24h后观察菌落数量,每个样品涂布3个平板。计算琼脂平板中的细菌菌落数量。
检测结果:
图14是水凝胶与大肠杆菌和金黄色葡萄球菌共培养后,10-6倍稀释后的涂布琼脂平板的抗菌效果。通过CFU计数确定各组的抗菌效果,空白组中金黄色葡萄球菌的菌落数平均为5.38×109CFU/ml,而不含纳米羟基磷灰石的复合水凝胶组和纳米羟基磷灰石复合水凝胶组的菌落数分别为1.2×109CFU/ml和1.65×109CFU/ml。空白组中大肠杆菌的菌落数平均为3.18×109CFU/ml,而不含纳米羟基磷灰石的复合水凝胶组和纳米羟基磷灰石复合水凝胶组的的菌落数为0.15×109CFU/ml和0.07×109CFU/ml(图15)。
从上述结果可以得出结论,凝胶组对细菌有很好的抑菌作用,当纳米羟基磷灰石被加入凝胶中后,并不影响水凝胶的抑菌率,反而使细菌的生长受到了更大的抑制,特别是对大肠杆菌的抗菌效果达到90%以上。
实施例7
统计学分析
使用Origin 8.0进行单因素方差分析(ANOVA),以确定数据的统计意义。P<0.05被认为具有统计学意义。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种纳米羟基磷灰石复合水凝胶,其特征在于,由多糖和纳米粒子在水性介质中交联而成;
所述纳米粒子包括纳米羟基磷灰石或包含纳米羟基磷灰石的粒子;
所述多糖包括葡聚糖、羧甲基壳聚糖、壳聚糖、透明质酸和羟乙基壳聚糖中的两种。
2.如权利要求1所述的纳米羟基磷灰石复合水凝胶,其特征在于,所述多糖为葡聚糖、羧甲基壳聚糖。
3.如权利要求1所述的纳米羟基磷灰石复合水凝胶,其特征在于,所述葡聚糖的分子量为10-200kDa,优选为20-150kDa。
4.如权利要求1所述的纳米羟基磷灰石复合水凝胶,其特征在于,所述纳米粒子的质量浓度为5-15wt%,优选为10wt%。
5.权利要求1-4任一项所述的纳米羟基磷灰石复合水凝胶的制备方法,其特征在于,包括以下步骤:
将一种多糖溶解在水性介质中,得到溶液A;
将纳米粒子加到溶液A中,得到溶液B;
将另一种多糖溶于水性介质中,得到溶液C;
将溶液B与溶液C混合,得到纳米羟基磷灰石复合水凝胶。
6.如权利要求5所述的纳米羟基磷灰石复合水凝胶的制备方法,其特征在于,溶液A的具体制备方法为:将葡聚糖和高碘酸钠溶解在水中并搅拌合成氧化葡聚糖溶液;
优选的,葡聚糖和高碘酸钠的摩尔比为1-3:1,进一步优选为2:1。
7.如权利要求5所述的纳米羟基磷灰石复合水凝胶的制备方法,其特征在于,溶液B的具体制备方法为:将纳米粒子加入到10wt%的溶液A中并均匀搅拌;
优选的,纳米粒子与10wt%的溶液A的比例为1:5-20,进一步优选为1:5。
8.如权利要求5所述的纳米羟基磷灰石复合水凝胶的制备方法,其特征在于,溶液C的具体制备方法为:将羧甲基壳聚糖溶于双蒸水中,得到羧甲基壳聚糖水溶液,优选的,羧甲基壳聚糖水溶液的浓度为10wt%。
9.如权利要求5所述的纳米羟基磷灰石复合水凝胶的制备方法,其特征在于,溶液B与溶液C的体积比为1-2:1-2,优选为1:1。
10.权利要求1-4任一项所述的纳米羟基磷灰石复合水凝胶在制备抗炎药物、止血材料中的应用,优选的,所述药物包括用于治疗牙周炎、牙龈炎、口腔溃疡。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211055899.8A CN115322451A (zh) | 2022-08-30 | 2022-08-30 | 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211055899.8A CN115322451A (zh) | 2022-08-30 | 2022-08-30 | 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115322451A true CN115322451A (zh) | 2022-11-11 |
Family
ID=83927790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211055899.8A Pending CN115322451A (zh) | 2022-08-30 | 2022-08-30 | 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115322451A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118085124A (zh) * | 2024-04-25 | 2024-05-28 | 山东劲脉植物细胞信息技术有限公司 | 一种β-1,3-葡聚糖的制备方法及其在生物诱导植物防病抗病中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120101535A1 (en) * | 2002-07-31 | 2012-04-26 | Atkinson Brent L | Bone repair putty |
CN107028872A (zh) * | 2015-07-21 | 2017-08-11 | 中国科学院化学研究所 | 一种复合水凝胶、其制备方法及应用 |
-
2022
- 2022-08-30 CN CN202211055899.8A patent/CN115322451A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120101535A1 (en) * | 2002-07-31 | 2012-04-26 | Atkinson Brent L | Bone repair putty |
CN107028872A (zh) * | 2015-07-21 | 2017-08-11 | 中国科学院化学研究所 | 一种复合水凝胶、其制备方法及应用 |
Non-Patent Citations (3)
Title |
---|
俞发 等: "正交试验确立氧化葡聚糖的制备条件", 《中国医院药学杂志》, vol. 27, no. 8, 18 August 2007 (2007-08-18), pages 1179 - 1180 * |
曹振: "壳聚糖/葡聚糖/纳米羟基磷灰石复合水凝胶引导骨再生的实验研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 2019, pages 10 - 6 * |
贾德民 等: "新型材料科学与技术 高分子材料卷 下", 华南理工大学出版社, pages: 2047 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118085124A (zh) * | 2024-04-25 | 2024-05-28 | 山东劲脉植物细胞信息技术有限公司 | 一种β-1,3-葡聚糖的制备方法及其在生物诱导植物防病抗病中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Injectable wound dressing based on carboxymethyl chitosan triple-network hydrogel for effective wound antibacterial and hemostasis | |
Li et al. | All-natural injectable hydrogel with self-healing and antibacterial properties for wound dressing | |
CN112300420B (zh) | 一种可注射抗菌互穿双网络水凝胶及其制备方法和应用 | |
Yoshino et al. | Applicability of bacterial cellulose as an alternative to paper points in endodontic treatment | |
EP2932989B1 (en) | Tissue sealant in which collagen and fibrin are mixed, and method for preparing same | |
CN112553785B (zh) | 一种双层引导组织再生膜及其制备方法 | |
CN111840631A (zh) | 可注射型抗菌止血水凝胶粘合剂及其制备方法和应用 | |
Lee et al. | Bioactivity and mechanical properties of collagen composite membranes reinforced by chitosan and β‐tricalcium phosphate | |
Salehi et al. | Kaolin-loaded chitosan/polyvinyl alcohol electrospun scaffold as a wound dressing material: In vitro and in vivo studies | |
Tavakoli et al. | Fabrication and evaluation of Cs/PVP sponge containing platelet-rich fibrin as a wound healing accelerator: An in vitro and in vivo study | |
Mirhaj et al. | Platelet rich fibrin containing nanofibrous dressing for wound healing application: Fabrication, characterization and biological evaluations | |
Cañas-Gutiérrez et al. | Bacterial cellulose: a biomaterial with high potential in dental and oral applications | |
CN110152055A (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
Li et al. | Microgel Assembly Powder Improves Acute Hemostasis, Antibacterial, and Wound Healing via In Situ Co‐Assembly of Erythrocyte and Microgel | |
CN115322451A (zh) | 一种纳米羟基磷灰石复合水凝胶及其制备方法和应用 | |
Do Amaral et al. | In vitro and in vivo response of composites based on chitosan, hydroxyapatite and collagen | |
CN109731141B (zh) | 一种引导组织修复的复合膜及其制备方法和应用 | |
Hu et al. | Fabrication and characterization of chitosan coated braided PLLA wire using aligned electrospun fibers | |
Wächter et al. | Imitating the microenvironment of native biofilms using nanofibrous scaffolds to emulate chronic wound infections | |
Priddy‐Arrington et al. | Characterization and Optimization of Injectable In Situ Crosslinked Chitosan‐Genipin Hydrogels | |
CN109125812A (zh) | 一种用于引导骨再生的复合膜及其制备方法 | |
CN112494712A (zh) | 一种具有止血和促骨愈合功能的可吸收海绵状骨蜡及其制备方法 | |
CN115337464B (zh) | 一种用于牙周组织修复的改性细菌纤维素膜的制备方法 | |
Salmasi et al. | Polysaccharide-based (kappa carrageenan/carboxymethyl chitosan) nanofibrous membrane loaded with antifibrinolytic drug for rapid hemostasis-in vitro and in vivo evaluation | |
Bao et al. | Bacteriosynthetic Degradable Tranexamic Acid‐Functionalized Short Fibers for Inhibiting Invisible Hemorrhage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |